封面
市場調查報告書
商品編碼
1616710

心房顫動設備市場機會、成長促進因素、產業趨勢分析與預測 2024 - 2032 年

Atrial Fibrillation Devices Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: | 出版商: Global Market Insights Inc. | 英文 100 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023 年,全球心房顫動設備市場估值為 106 億美元,預計 2024 年至 2032 年複合年成長率為 11.5%。來越多採用心臟消融手術,並提高了對早期診斷的意識。心房顫動的發生率在全球範圍內呈上升趨勢,使其成為最常見的心律不整類型。影響因素包括人口老化以及肥胖、高血壓和其他心血管疾病發生率的增加。全球有數百萬人受到影響,對診斷和治療設備的需求正在增加。

患者和醫療保健提供者對心房顫動的認知不斷提高,可以更及時地進行診斷和治療。公共衛生措施和教育活動強調了監測和管理 AF 的重要性,從而增加了對 AF 設備的需求。早期檢測對於預防中風等併發症至關重要,這反過來又推動了診斷和監測工具的使用。心房顫動設備是用於診斷、監測和治療 AFib(一種常見的心律不整)的重要醫療工具。

其中包括用於除顫器的導管、植入式心臟監視器、消融手術以及幫助調節心律的心律調節器。他們的主要目標是恢復正常的心臟功能、預防中風和緩解心房顫動相關症狀。這些設備在 AFib 患者的急性和長期治療中發揮著至關重要的作用。市場按產品細分,包括心臟監視器、電生理消融導管、標測系統、電生理診斷導管、接取裝置、左心耳封堵裝置、心內超音波心臟檢查 (ICE) 和其他相關產品。

市場範圍
開始年份 2023年
預測年份 2024-2032
起始值 106 億美元
預測值 279 億美元
複合年成長率 11.5%

電生理消融導管部門獲得了最高的收入,這得益於提高消融手術安全性和有效性的技術進步。導管設計的創新和改進的能量輸送系統擴大了可以從消融中受益的患者範圍,進一步推動了市場成長。就最終用途而言,心房顫動設備市場分為門診手術中心、醫院、心臟中心等。由於對需要各種 AF 設備進行診斷、治療和患者監護的專業治療中心的需求不斷成長,醫院細分市場將在 2023 年引領市場。

北美房顫設備市場 2023 年收入達 43 億美元,預計 2024 年至 2032 年複合年成長率為 11.3%。北美的高醫療保健支出支持對先進醫療技術(包括心房顫動設備)的大量投資,刺激了市場成長。

目錄

第 1 章:方法與範圍

第 2 章:執行摘要

第 3 章:產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 先進技術的高採用率和先進的醫療基礎設施
      • 心血管疾病盛行率增加
      • 老年人口不斷增加
      • 風濕性瓣膜性心臟病盛行率上升
    • 產業陷阱與挑戰
      • 與心房顫動設備相關的高成本
      • 發展中國家對增強醫療技術缺乏認知
  • 成長潛力分析
  • 監管環境
  • 技術景觀
  • 報銷場景
  • 2021 - 2023 年全球和區域層面的心房顫動導管消融手術
    • 全球的
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 導管消融中心,依地區分類,2021 - 2023
    • 全球的
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • MEA
  • 定價分析
  • 差距分析
  • 波特的分析
  • PESTEL分析

第 4 章:競爭格局

  • 介紹
  • 公司矩陣分析
  • 公司市佔率分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章:市場估計與預測:按產品分類,2021 - 2032 年

  • 主要趨勢
  • EP消融導管
    • 射頻 (RF)
    • 雷射
    • 冷凍消融
    • 超音波
    • 微波
    • 其他 EP 消融導管
  • 心臟監測儀或植入式循環記錄儀
  • EP診斷導管
    • 先進的標測導管
    • 可操縱導管
    • 固定曲線導管
  • 測繪和記錄系統
  • 存取裝置
  • 心內超音波心動圖(ICE)
  • 左心耳 (LAA) 封堵器
  • 其他產品

第 6 章:市場估計與預測:按最終用途分類,2021 - 2032 年

  • 主要趨勢
  • 醫院
  • 心臟中心
  • 門診手術中心
  • 其他最終用戶

第 7 章:市場估計與預測:按地區,2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 8 章:公司簡介

  • Abbott Laboratories
  • Acutus Medical, Inc.
  • AtriCure, Inc.
  • Biotronik
  • Boston Scientific Corporation
  • CardioFocus
  • CathRx Ltd.
  • Hansen Medical, Inc.
  • Imricor
  • Johnson and Johnson (Biosense Webster)
  • Medtronic plc
  • MicroPort Scientific Corporation
  • OSYPKA MEDICAL
  • Stryker Corporation
  • Synaptic Medical
簡介目錄
Product Code: 3165

The Global Atrial Fibrillation Devices Market was valued at USD 10.6 billion in 2023 and is projected to grow at a CAGR of 11.5% from 2024 to 2032. This robust growth is primarily driven by advancements in atrial fibrillation devices, a rising prevalence of AF, an increasing adoption of cardiac ablation procedures, and heightened awareness leading to early diagnosis. The incidence of atrial fibrillation is on the rise globally, making it the most common type of cardiac arrhythmia. Contributing factors include aging populations and increasing rates of obesity, hypertension, and other cardiovascular conditions. With millions affected worldwide, the demand for both diagnostic and treatment devices is escalating.

Increased awareness about atrial fibrillation among patients and healthcare providers has led to more timely diagnoses and treatment. Public health initiatives and educational campaigns highlight the importance of monitoring and managing AF, boosting demand for AF devices. Early detection is crucial to preventing complications like stroke, which in turn drives the use of diagnostic and monitoring tools. Atrial fibrillation devices are essential medical tools used to diagnose, monitor, and treat AFib, a common heart rhythm disorder.

These include catheters for defibrillators implantable cardiac monitors, ablation procedures, and pacemakers that help regulate heart rhythm. Their main goals are to restore normal heart function, prevent strokes, and alleviate AFib-related symptoms. These devices play a vital role in both the acute and long-term management of AFib patients. The market is segmented by product, including cardiac monitors, EP ablation catheters, mapping systems, EP diagnostic catheters, access devices, left atrial appendage closure devices, intracardiac echocardiography (ICE), and other related products.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$10.6 Billion
Forecast Value$27.9 Billion
CAGR11.5%

The EP ablation catheters segment garnered the highest revenue, driven by technological advancements that enhance safety and efficacy in ablation procedures. Innovations in catheter design and improved energy delivery systems have expanded the range of patients who can benefit from ablation, further propelling market growth. In terms of end-use, the atrial fibrillation devices market is divided into ambulatory surgical centers, hospitals, cardiac centers, and others. The hospitals segment led the market in 2023, fueled by the increasing need for specialized treatment centers that require a variety of AF devices for diagnosis, treatment, and patient monitoring.

The North America atrial fibrillation devices market amassed USD 4.3 billion in revenue in 2023 and is expected to grow at a CAGR of 11.3% from 2024 to 2032. This region's high prevalence of AF is influenced by an aging population and a rise in lifestyle-related conditions. High healthcare expenditure in North America supports significant investments in advanced medical technologies, including atrial fibrillation devices, stimulating market growth.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 High adoption rate of advanced technologies and presence of sophisticated healthcare infrastructure
      • 3.2.1.2 Increase in prevalence of cardiovascular diseases
      • 3.2.1.3 Rising geriatric population
      • 3.2.1.4 Rise in prevalence of rheumatic valvular heart diseases
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost associated with atrial fibrillation devices
      • 3.2.2.2 Lack of awareness regarding enhanced medical technologies in developing countries
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technology landscape
  • 3.6 Reimbursement scenario
  • 3.7 Atrial fibrillation catheter ablation procedures at global and regional level, 2021 - 2023
    • 3.7.1 Global
    • 3.7.2 North America
    • 3.7.3 Europe
    • 3.7.4 Asia Pacific
    • 3.7.5 Latin America
    • 3.7.6 Middle East & Africa
  • 3.8 Catheter ablation centres, by region, 2021 - 2023
  • 3.9 Atrial fibrillation devices market, 2021 -2032 (Units)
    • 3.9.1 Global
    • 3.9.2 North America
    • 3.9.3 Europe
    • 3.9.4 Asia Pacific
    • 3.9.5 Latin America
    • 3.9.6 MEA
  • 3.10 Pricing analysis
  • 3.11 Gap analysis
  • 3.12 Porter's analysis
  • 3.13 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 EP ablation catheters
    • 5.2.1 Radiofrequency (RF)
    • 5.2.2 Laser
    • 5.2.3 Cryoablation
    • 5.2.4 Ultrasound
    • 5.2.5 Microwave
    • 5.2.6 Other EP ablation catheters
  • 5.3 Cardiac monitors or implantable loop recorder
  • 5.4 EP diagnostic catheters
    • 5.4.1 Advanced mapping catheters
    • 5.4.2 Steerable catheters
    • 5.4.3 Fixed curve catheters
  • 5.5 Mapping and recording systems
  • 5.6 Access devices
  • 5.7 Intracardiac echocardiography (ICE)
  • 5.8 Left atrial appendage (LAA) closure devices
  • 5.9 Other products

Chapter 6 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Hospitals
  • 6.3 Cardiac centers
  • 6.4 Ambulatory surgical centers
  • 6.5 Other end-users

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 France
    • 7.3.4 Spain
    • 7.3.5 Italy
    • 7.3.6 Netherlands
    • 7.3.7 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 South Korea
    • 7.4.6 Rest of Asia Pacific
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Mexico
    • 7.5.3 Argentina
    • 7.5.4 Rest of Latin America
  • 7.6 Middle East and Africa
    • 7.6.1 South Africa
    • 7.6.2 Saudi Arabia
    • 7.6.3 UAE
    • 7.6.4 Rest of Middle East and Africa

Chapter 8 Company Profiles

  • 8.1 Abbott Laboratories
  • 8.2 Acutus Medical, Inc.
  • 8.3 AtriCure, Inc.
  • 8.4 Biotronik
  • 8.5 Boston Scientific Corporation
  • 8.6 CardioFocus
  • 8.7 CathRx Ltd.
  • 8.8 Hansen Medical, Inc.
  • 8.9 Imricor
  • 8.10 Johnson and Johnson (Biosense Webster)
  • 8.11 Medtronic plc
  • 8.12 MicroPort Scientific Corporation
  • 8.13 OSYPKA MEDICAL
  • 8.14 Stryker Corporation
  • 8.15 Synaptic Medical